PepGen Inc.(PEPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PEPG PepGen Inc.

Post-Mkt 03-13 16:58:53 EDT

5.33

-0.82

-13.41%

盘后5.33

+0.00+0.09%

16:43 EDT

High6.31	Low5.32	Vol1.34M
Open6.22	D1 Closing6.15	Amplitude16.02%
Mkt Cap368.04M	Tradable Cap243.76M	Total Shares69.12M
T/O7.58M	T/O Rate2.93%	Tradable Shares45.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PEPG","market":"US","secType":"STK","nameCN":"PepGen Inc.","latestPrice":5.325,"timestamp":1773432000000,"preClose":6.15,"halted":0,"volume":1338980,"hourTrading":{"tag":"盘后","latestPrice":5.33,"preClose":5.325,"latestTime":"16:43 EDT","volume":225976,"amount":1215654.2526624,"timestamp":1773434581179,"change":0.005,"changeRate":0.000939,"amplitude":0.022535},"delay":0,"changeRate":-0.13414634146341464,"floatShares":45776899,"shares":69115292,"eps":-2.123428,"marketStatus":"Post-Mkt","change":-0.825,"latestTime":"03-13 16:58:53 EDT","open":6.22,"high":6.305,"low":5.32,"amount":7582462.9777,"amplitude":0.160163,"askPrice":5.33,"askSize":125,"bidPrice":5.21,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-2.123428,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773446400000},"marketStatusCode":4,"adr":0,"listingDate":1651809600000,"exchange":"NASDAQ","adjPreClose":6.15,"preHourTrading":{"tag":"盘前","latestPrice":6.12,"preClose":6.15,"latestTime":"07:00 EDT","volume":100,"amount":612,"timestamp":1773399608663,"change":-0.03,"changeRate":-0.004878,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":5.33,"preClose":5.325,"latestTime":"16:43 EDT","volume":225976,"amount":1215654.2526624,"timestamp":1773434581179,"change":0.005,"changeRate":0.000939,"amplitude":0.022535},"volumeRatio":2.185662,"impliedVol":0.9001,"impliedVolPercentile":0.4064},"requestUrl":"/m/hq/s/PEPG","defaultTab":"news","newsList":[{"id":"2617578879","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2617578879","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617578879?lang=en_us&edition=fundamental","pubTime":"2026-03-06 03:02","pubTimestamp":1772737341,"startTime":"0","endTime":"0","summary":"Distribution Solutions Group  reported Thursday Q4 adjusted earnings below estimates, and sales also missed the forecast.Shares slumped 27% following an increase in intraday trading volume to over 252,000 from a daily average of about 76,000.Grocery Outlet's  shares sank 26% after the company reported overnight fiscal 2026 adjusted earnings and revenue guidance that trailed analysts' estimates.More than 10.3 million shares of the company traded intraday compared with a daily average of about 2.48 million.PepGen  said late Wednesday that the US Food and Drug Administration placed a partial clinical hold on the phase 2 trial of PGN-EDODM1 for the potential treatment of myotonic dystrophy type 1, a multisystem disorder that affects skeletal and smooth muscle.Shares dropped 18%, with intraday trading volume at over 2.55 million versus a daily average of roughly 652,000.Price: 21.75, Change: -7.96, Percent Change: -26.79","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4104","BK4113","DSGR","GO","LU0471298777.SGD","LU0385154629.USD","PEPG"],"gpt_icon":0},{"id":"2617568521","title":"Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Compass Therapeutics (CMPX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617568521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617568521?lang=en_us&edition=fundamental","pubTime":"2026-03-05 23:50","pubTimestamp":1772725807,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PepGen Inc. (PEPG – Research Report) and Compass The...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pepgen-inc-pepg-and-compass-therapeutics-cmpx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pepgen-inc-pepg-and-compass-therapeutics-cmpx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","LABU","BK4137","LU0029874061.USD","BK4581","XBI","BK4588","HCSG","CMPX","PEPG","XLV","BK4139","BK4585"],"gpt_icon":0},{"id":"2617230985","title":"Wedbush Reaffirms Their Buy Rating on PepGen Inc. (PEPG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617230985","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617230985?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:15","pubTimestamp":1772720148,"startTime":"0","endTime":"0","summary":"In a report released today, from Wedbush maintained a Buy rating on PepGen Inc., with a price target of $9.00. In addition to Wedbush, PepGen Inc. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-reaffirms-their-buy-rating-on-pepgen-inc-pepg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-reaffirms-their-buy-rating-on-pepgen-inc-pepg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PEPG"],"gpt_icon":0},{"id":"2617754642","title":"PepGen Shares Fall After FDA Puts Myotonic Dystrophy Trial on Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2617754642","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617754642?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:25","pubTimestamp":1772709900,"startTime":"0","endTime":"0","summary":"Shares of PepGen slid after the Food and Drug Administration put a partial clinical hold on a study of its treatment for Myotonic Dystrophy, a genetic disorder that causes progressive muscle loss and weakness.The stock fell 19% to $5.50 in Thursday's off-hours trading. It has more than doubled over the past 52 weeks.The company said the FDA raised questions related to previously- submitted preclinical pharmacology and toxicology studies.PepGen said it \"is committed to working with the FDA to address the Agency's questions as quickly as possible.\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"gpt_icon":0},{"id":"2617156083","title":"Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems","url":"https://stock-news.laohu8.com/highlight/detail?id=2617156083","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617156083?lang=en_us&edition=fundamental","pubTime":"2026-03-05 07:24","pubTimestamp":1772666640,"startTime":"0","endTime":"0","summary":"Broadcom expects revenue in the current quarter ahead of expectations thanks to growing AI demand. The stock advanced 5% to $332.82 in after-hours trading Wednesday.StubHub swung to a loss and posted lower revenue as it invests in AI to build a supply management platform. Shares slid 12% to $8.97 after the bell.PepGen said the FDA is pausing a trial of its myotonic dystrophy treatment. The stock shed 19% to $5.50.Veeva Systems' revenue and profit rose. Shares gained 13% to $212.76.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0004445015.USD","LU1868836914.USD","IE00BMPRXQ63.HKD","LU2458330169.SGD","LU2065171311.SGD","BK4534","AVGW","LU0965509010.AUD","LU2125154935.USD","LU1629891620.HKD","LU0079474960.USD","LU0256863902.USD","BK4598","IE00BN29S564.USD","STUB","LU0912757837.SGD","LU0170899867.USD","LU1145028129.USD","IE00BGHQDM52.EUR","LU1323610961.USD","LU2247934214.USD","LU2168564149.EUR","LU1778281490.HKD","LU2361044865.SGD","LU1691799644.USD","SG9999011175.SGD","LU0784385170.HKD","LU2211815571.USD","LU0323591593.USD","IE00BWXC8680.SGD","SGXZ99366536.SGD","LU1989764664.SGD","BK4528","IE0034235188.USD","LU1670711123.USD","LU0096364046.USD","IE0034235303.USD","LU1366333091.USD","LU1366192091.USD","LU0708995401.HKD","LU2462157665.USD","LU2265009873.SGD","LU0225283273.USD","LU0957808578.USD","LU0198837287.USD","AVGX","LU2242649171.HKD","LU0058720904.USD","PEPG","LU1992135472.HKD","LU0069063385.USD","LU2931357623.SGD","LU1551013425.SGD","LU0942090050.USD","IE00B19Z9Z06.USD","LU2213496289.HKD","LU0048584097.USD","LU0203202063.USD","LU0553294199.USD","LU2764262908.HKD","LU2430703095.HKD","LU1814569148.SGD","LU2041044095.USD","LU0787776722.HKD","IE0004445239.USD","LU2322448791.USD","BK4613","IE00BJTD4N35.SGD","LU2298321311.HKD","LU0109392836.USD","LU1935043023.USD","LU2279689827.SGD","LU1244550577.SGD","LU2063271972.USD","LU2023250843.SGD","IE00BMCWC346.EUR","LU2720916845.USD","IE00BZ9MQY76.HKD","AVGO","LU0823434740.USD","LU0210533765.USD","LU0719512351.SGD","LU0096362180.USD","LU0210528500.USD","LU1992135399.USD","LU0820561909.HKD","IE00BKVL7J92.USD","LU1153585028.USD","LU0889565833.HKD","LU2505996509.AUD","LU0082616367.USD","LU2458330243.SGD","LU1232071149.USD","SG9999015986.USD","LU0215105999.USD","LU2089985449.USD","LU2456880835.USD","LU0943347566.SGD","SGXZ23171101.USD","LU0203347892.USD","LU2471134879.HKD","LU0545039389.USD","LU2250418816.HKD","IE00B775SV38.USD","SG9999004303.SGD","LU1988902786.USD","LU1670711040.USD","LU2471134796.USD","LU2087625088.SGD","LU2236285917.USD","LU0320765059.SGD","LU0234572021.USD","IE00BKDWB100.SGD","LU1674673428.USD","LU0154236417.USD","LU2357305700.SGD","LU2168564222.USD","LU0057025933.USD","LU0266013472.USD","LU0348723411.USD","LU2750360997.AUD","IE0009356076.USD","LU0006306889.USD","LU2602419157.SGD","LU1868837136.USD","SG9999003800.SGD","LU1316542783.SGD","LU2360108059.USD","LU2125154778.USD","SG9999002232.USD","LU1670628061.USD","BK4533","LU1934455277.USD","LU0345770308.USD","LU2347655156.SGD","BK4108","IE00BKPKM429.USD","LU2054465674.USD","LU0861579265.USD","IE00BDGV0183.EUR","LU2065171402.SGD","BK4192","LU2505996681.GBP","IE0005OL40V9.USD","LU1242518857.USD","IE00BLSP4239.USD","LU0868494617.USD","LU0472753341.HKD","LU0444971666.USD","LU1935043536.SGD","LU2133065610.SGD","LU0964807845.USD","LU2592432038.USD","LU0080751232.USD","IE00BMPRXR70.SGD","IE00B7KXQ091.USD","LU2487616109.SGD","LU1242518931.SGD","BK4551","LU1037948541.HKD","LU0353189680.USD","LU2237443382.USD","LU1720051017.SGD","LU0061475181.USD","LU2361045086.USD","LU2896262040.SGD","SG9999001440.SGD","LU0251132253.USD","LU0097036916.USD","LU0345768153.USD","LU2023250504.SGD","LU2237443978.SGD","LU1003077747.HKD","LU0726765562.USD","IE00BGHQF631.EUR","LU0795875169.SGD","LU1162221912.USD","IE00BJLML261.HKD","LU0689626769.HKD","BK4543","LU0289739343.SGD","IE00B19Z9P08.USD","LU0345769631.USD","LU0056508442.USD","LU2430703178.SGD","LU0957791311.USD","LU1623119135.USD","IE00BJTD4V19.USD","IE00BQXX3D17.EUR","LU2463028550.USD","LU0985320562.USD","LU2237957811.SGD","LU2092937221.SGD","LU2168564495.EUR","IE00BFSS7M15.SGD","LU2211814178.USD","LU1244550494.USD","LU0965509283.SGD","LU1815336760.USD","BK4504","SG9999015945.SGD","LU1280957306.USD","LU2264538146.SGD","LU2756315664.SGD","LU0642271901.SGD","LU0949170426.SGD","LU0053666078.USD","BK4575","LU2420271590.USD","LU0672654240.SGD","BK4141","LU2746668461.USD","LU2361044949.HKD","LU1069344957.HKD","LU0784385840.USD","LU0124676726.USD","LU2355687059.USD","SG9999015978.USD","IE00BZ1G4Q59.USD","LU1035775433.USD","LU0345769128.USD","LU0157215616.USD","LU0106261372.USD","SG9999002224.SGD","LU0823434583.USD","BK4605","IE00B3S45H60.SGD","IE00B5949003.HKD","LU2108987350.USD","LU1267930730.SGD","LU1712237335.SGD","LU1974910355.USD","LU1037948897.HKD","SGXZ81514606.USD","AVGG","LU0127658192.USD","LU0683600562.USD","LU0476273544.USD","BK4585","LU1670710661.SGD","LU0640476718.USD","BK4566","LU0011850046.USD","LU0444973449.USD","IE00BJJMRX11.SGD","LU1244550221.USD","LU2272731600.USD","LU1914381329.SGD","LU0256863811.USD","BK4554","LU0795875086.SGD","AVGU","BK4581","IE00BFSS8Q28.SGD","LU0511384066.AUD","LU2272731865.HKD","LU1127390331.HKD","IE0001KFT4U8.USD","LU0466842654.USD","LU1732800096.USD","LU1935042215.USD","LU0965509101.SGD","IE00BLSP4452.SGD","LU1670627923.USD","LU0316494557.USD","LU0784384876.USD","LU0738911758.USD","LU2471134952.CNY","LU1989764748.USD","LU2347655073.USD","LU2360032135.SGD","LU0354030438.USD","BK4167","LU1852331112.SGD","LU1670710588.SGD","LU2244417387.USD","IE00B775H168.HKD","LU0203345920.USD","LU1934455863.HKD","AVS","IE00BQXX3F31.USD","BK4515","IE00B3PB1722.GBP","LU0979878070.USD","LU2272731782.SGD","LU2746668974.SGD","LU2764263039.SGD","SGXZ51526630.SGD","IE00B1XK9C88.USD","LU2322448957.HKD","LU0786609619.USD","LU1935042488.USD","IE00B894F039.SGD","LU2242650005.HKD","IE00BK4W5M84.HKD","IE00B42XCP33.USD","LU2168564065.EUR","LU1935042991.SGD","LU1868837300.USD","LU2168563687.JPY","LU0868494708.USD","LU0238689110.USD","LU0210536198.USD","LU2237443895.HKD","LU2403377893.USD","LU2065170008.USD","LU2065169927.USD","LU2106854487.HKD","LU1732799900.SGD","LU1804176565.USD","LU1868836757.USD","LU2430703251.USD","LU1815333072.USD","IE00BVYPNP33.GBP","LU0417517546.SGD","LU0965508806.USD","LU1548497426.USD","LU2237443622.USD","SG9999015952.SGD","LU0234570918.USD","LU2360106780.USD","LU2083900584.USD","AVL","LU0784383803.USD","IE00BK4W5L77.USD","LU2237443465.HKD","IE00BMPRXN33.USD","IE00BVYPNW00.USD","LU1642822529.SGD","LU1868836591.USD","LU1720051108.HKD","BK4512","IE00BBT3K403.USD","LU2543165471.USD","LU1934455194.USD","LU2237443549.SGD","LU2417539215.USD","LU2237957902.USD","LU1674673691.USD","LU0289739699.SGD","LU2471134523.USD","LU2237438978.USD","BK4612","LU2286300806.USD","LU2750360641.GBP","LU0061474960.USD","VEEV","IE00B4JS1V06.HKD","IE00BJJMRY28.SGD","LU1064131342.USD","IE00BVYPNQ40.USD","LU0203201768.USD","LU2461242641.AUD","LU1551013342.USD","BK4588","IE00B1BXHZ80.USD","LU0289961442.SGD","LU0109391861.USD","LU0353189763.USD","SG9999001424.SGD","LU2764263203.CNY","IE00BYV24P56.USD","LU0689472784.USD","IE00BN8TJ469.HKD","LU0820562030.AUD","LU0949170772.SGD","LU2473716301.USD","LU0081259029.USD","LU1301847155.USD","LU2756315318.SGD","LU2860962120.EUR","LU2023250330.USD","BK4139","LU0345768740.USD","LU0820561818.USD","LU0187121727.USD","LU0320765646.SGD","LU1803068979.SGD","LU0661504455.SGD","LU0345770993.USD","LU1917777945.USD","IE00BVYPNV92.GBP","IE00BQXX3C00.GBP","LU0354030511.USD","LU0274383776.USD"],"gpt_icon":1},{"id":"2617564047","title":"PepGen Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2617564047","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617564047?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:16","pubTimestamp":1772662606,"startTime":"0","endTime":"0","summary":"PepGen Inc reports results for the quarter ended December 31 - Earnings SummaryPepGen Inc PEPG.OQ reported a quarterly adjusted loss of 27 cents per share for the quarter ended December 31, higher tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL8N3ZS32R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2617564980","title":"BUZZ-PepGen falls after US FDA puts partial hold on mid‑stage drug trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2617564980","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617564980?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:01","pubTimestamp":1772661718,"startTime":"0","endTime":"0","summary":"BUZZ-PepGen falls after US FDA puts partial hold on midstage drug trial** Shares of drug developer PepGen PEPG.O fall 17% to $5.60 in extended trading** PEPG says the U.S. FDA has put a partial clinical hold on its midstage trial of a rare muscle disease drug** The drug, PGNEDODM1, is being tested for myotonic dystrophy type 1, which causes progressive muscle weakness** Co says the health regulator's concerns relate to earlier lab and animal studies the company submitted** PEPG says it's working with the FDA to address the questions and will submit additional info** PEPG rose 72.7% in 2025  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL4N3ZS26S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"gpt_icon":0},{"id":"2617872561","title":"BRIEF-Pepgen Inc - U.S. FDA Places FREEDOM2 Trial On Partial Clinical Hold Related To Preclinical Pharmacology And Toxicology","url":"https://stock-news.laohu8.com/highlight/detail?id=2617872561","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617872561?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:28","pubTimestamp":1772659697,"startTime":"0","endTime":"0","summary":"BRIEF-Pepgen Inc - U.S. FDA Places FREEDOM2 Trial On Partial Clinical Hold Related To Preclinical Pharmacology And ToxicologyMarch 4 (Reuters) - PepGen Inc PEPG.O:PEPGEN INC: U.S. FDA PLACES FREEDOM2 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS1YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2617569734","title":"PepGen reports Q4 EPS (27c), consensus (39c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569734","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569734?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:19","pubTimestamp":1772659161,"startTime":"0","endTime":"0","summary":"“2025 was a transformative year for PepGen (PEPG) as the Phase 1 FREEDOM trial delivered compelling data that set a new benchmark for splicing corr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pepgen-reports-q4-eps-27c-consensus-39c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pepgen-reports-q4-eps-27c-consensus-39c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PEPG","BK4139"],"gpt_icon":0},{"id":"2617569393","title":"PepGen Q4 EPS $(0.27) Beats $(0.36) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569393","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569393?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:08","pubTimestamp":1772658538,"startTime":"0","endTime":"0","summary":"PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.36) by 25.41 percent. This is a 60.29 percent increase over losses of $(0.68) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51050815/pepgen-q4-eps-0-27-beats-0-36-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"PepGen Q4 EPS $(0.27) Beats $(0.36) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"gpt_icon":0},{"id":"2617569068","title":"PepGen Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569068","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569068?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:07","pubTimestamp":1772658459,"startTime":"0","endTime":"0","summary":"16:01 EST PepGen (PEPG) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pepgen-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pepgen-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PEPG","BK4139"],"gpt_icon":0},{"id":"2617569819","title":"PepGen Q4 net loss narrows 17.4% to USD 18.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569819","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569819?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:06","pubTimestamp":1772658403,"startTime":"0","endTime":"0","summary":"PepGen Q4 net loss narrows 17.4% to USD 18.3 million               PepGen reported a Q4 net loss of USD 18.3 million and a basic and diluted net loss per share of USD 0.27. R&D expenses were USD 13.9 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL7dJr1H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2617727566","title":"BRIEF-PepGen Q4 EPS USD -0.27","url":"https://stock-news.laohu8.com/highlight/detail?id=2617727566","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617727566?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:05","pubTimestamp":1772658346,"startTime":"0","endTime":"0","summary":"BRIEF-PepGen Q4 EPS USD -0.27\n\n\nMar 04 (Reuters) - PepGen Q4 net income USD -18.34 million.\n\nQ4 operating income USD -19.705 million\nQ4 operating expenses USD 19.705 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nPLX4D8558:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2617056627","title":"PepGen Q4 Operating Expenses USD 19.705 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617056627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617056627?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:05","pubTimestamp":1772658301,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nPLX4D8558:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2617566770","title":"Press Release: PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2617566770","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617566770?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:05","pubTimestamp":1772658300,"startTime":"0","endTime":"0","summary":"-- FREEDOM2-DM1 5 mg/kg cohort data expected in Q1 2026 --. -- Patient dosing in the FREEDOM2 10 mg/kg cohort is proceeding in Canada and the UK, with data expected in 2H 2026 --. -- FREEDOM2 trial open in South Korea, Australia, and New Zealand --. -- Well-funded with $148.5M of cash as of December 31, 2025, sufficient to fund operations into the second half of 2027 --. PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the quarter and year-ended December 31, 2025, and recent corporate highlights.mg/kg dose. PepGen has since dosed 50% of patients (4/8) in the 10","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","LU0728928796.USD","LU2413665964.HKD","LU1620156213.USD","LU1596574779.USD","LU0106261612.USD","IE00BN0W2T93.GBP","BK4139","LU0054578231.USD","LU2229751404.USD","LU1169589451.USD","LU1620156130.USD","LU1169590202.USD","IE00BN0W2W23.USD","LU2125910179.SGD","LU0757428866.USD","LU1543694498.USD","WMS","LU1165135440.EUR","BK4086","LU1815336091.USD","LU2089279066.USD","LU1923621640.USD","MDA","LU2125910336.SGD","LU0012050646.USD","PEPG","LU2413666004.HKD","LU2308191902.HKD","LU1721427968.SGD"],"gpt_icon":0},{"id":"2617566423","title":"FDA places partial clinical hold on PepGen’s FREEDOM2-DM1 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2617566423","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617566423?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:03","pubTimestamp":1772658194,"startTime":"0","endTime":"0","summary":"PepGen Inc. said the U.S. Food and Drug Administration has placed a partial clinical hold on the U.S. portion of its FREEDOM2-DM1 Phase 2 trial of PGN-EDODM1 for myotonic dystrophy type 1, citing questions related to previously submitted preclinical pharmacology and toxicology studies. The company said the hold was not based on blinded Phase 1 clinical data, no U.S. patients have been enrolled in FREEDOM2, and it is submitting additional analyses, including recently unblinded FREEDOM data, to address the FDA’s concerns.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PepGen Inc. published the original content used to generate this news brief via Business Wire  on March 04, 2026, and is solely responsible for the information contained th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL2h6vJF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"gpt_icon":0},{"id":"2617566498","title":"PepGen Inc - Receives Regulatory Clearance to Initiate Freedom2 in South Korea, Australia, and New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2617566498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617566498?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:03","pubTimestamp":1772658192,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS1YQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2617556649","title":"PepGen Inc: U.S. FDA Places Freedom2 Trial on Partial Clinical Hold Related to Preclinical Pharmacology and Toxicology","url":"https://stock-news.laohu8.com/highlight/detail?id=2617556649","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617556649?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:03","pubTimestamp":1772658192,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS1YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2617492566","title":"PepGen Inc: Reiterates Guidance for Reporting Data From Freedom2 5 Mg/Kg Cohort in Q1 2026 and From 10 Mg/Kg Cohort in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2617492566","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617492566?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:03","pubTimestamp":1772658192,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS1YQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PEPG"],"gpt_icon":0},{"id":"2617661755","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 04:01 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2617661755","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617661755?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:01","pubTimestamp":1772658060,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 04:01 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nAQN2LOS2K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pepgen.com","stockEarnings":[{"period":"1week","weight":0.1172},{"period":"1month","weight":0.1162},{"period":"3month","weight":0.0866},{"period":"6month","weight":3.1554},{"period":"1year","weight":1.4899},{"period":"ytd","weight":-0.0553}],"compareEarnings":[{"period":"1week","weight":-0.0224},{"period":"1month","weight":-0.0377},{"period":"3month","weight":-0.023},{"period":"6month","weight":0.0132},{"period":"1year","weight":0.1918},{"period":"ytd","weight":-0.0233}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.057082},{"month":2,"riseRate":0.75,"avgChangeRate":0.580465},{"month":3,"riseRate":0,"avgChangeRate":-0.224262},{"month":4,"riseRate":0.666667,"avgChangeRate":0.062221},{"month":5,"riseRate":0.333333,"avgChangeRate":0.08415},{"month":6,"riseRate":0,"avgChangeRate":-0.194547},{"month":7,"riseRate":0.5,"avgChangeRate":-0.062921},{"month":8,"riseRate":0.25,"avgChangeRate":-0.102699},{"month":9,"riseRate":0.25,"avgChangeRate":0.658187},{"month":10,"riseRate":0.75,"avgChangeRate":0.035806},{"month":11,"riseRate":0.5,"avgChangeRate":0.080021},{"month":12,"riseRate":0.5,"avgChangeRate":0.010709}],"exchange":"NASDAQ","name":"PepGen Inc.","nameEN":"PepGen Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PepGen Inc.(PEPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest PepGen Inc.(PEPG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"PepGen Inc.,PEPG,PepGen Inc.股票,PepGen Inc.股票老虎,PepGen Inc.股票老虎国际,PepGen Inc.行情,PepGen Inc.股票行情,PepGen Inc.股价,PepGen Inc.股市,PepGen Inc.股票价格,PepGen Inc.股票交易,PepGen Inc.股票购买,PepGen Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PepGen Inc.(PEPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest PepGen Inc.(PEPG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}